- 期刊
Durable Ceritinib Response in Stage IV Lung Adenocarcinoma Patients Harboring the Anaplastic Lymphoma Kinase Fusion Gene: Long Term Follow-up in a Tertiary Care Medical Center
摘要
Introduction: Advanced-stage lung adenocarcinoma patients harboring the anaplastic lymphoma kinase (ALK) fusion gene show a good response to ALK tyrosine kinase inhibitors (TKIs). Ceritinib, the first FDA-approved second-generation ALK TKI, has shown potent effects in clinical trials. Here, we evaluated the long-term clinical outcomes of patients treated with ceritinib. Methods: We retrospectively reviewed patients who started ceritinib treatment between April 2013 and August 2017. The medical records and diagnostic images of the patients, as well as the local treatment methods, were retrospectively reviewed. Results: Overall, 23 patients were included and a response rate of 74% was observed. With a median follow-up of 42.1 months, the median progression-free survival was 15 months (95% confidence interval, 11.6-19.5), and median overall survival had not been reached by July 31, 2019. Twelve patients (52.2%) received ceritinib beyond progression, with 8 receiving additional local treatment upon disease progression. Treatment duration after progression ranged between 2.7 and 65.5 months, with a median of 31.4 months. Conclusion: Ceritinib is well tolerated in clinical settings. Patients with advanced-stage lung adenocarcinoma harboring ALK mutations could achieve favorable long-term outcomes through multimodality treatment.